our mission

To develop and commercialize self-administered parenteral medicines that optimize clinical benefits with enhanced cost effective health outcomes

news / press releases

  • 27 April 2016

    Antares Pharma to Present at the Deutsche Bank Securities,INC. 41st Annual Healthcare Conference
  • 25 April 2016

    Otrexup.com website awarded a Bronze Horizon Interactive Award
  • 5 April 2016

    Antares Pharma Discloses "Pen 1" Development Project as Teriparatide
  • 29 March 2016

    Additional dosage strengths of Otrexup Methotrexate Injection approved by the FDA
  • 16 March 2016

    Antares Announces Completion of the 52 week Quickshot Phase 3 Study in Testosterone Deficient Men
  • 8 March 2016

    Antares Pharma Reports Fourth Quarter and Full Year 2015 Financial and Operating Results

latest products & technology

 

Otrexup (methotrexate) injection for subcutaneous use only.

Learn More >>